Treatment Outcome of Autologous PRP Versus Conventional Therapy Among

Status Completed

Clinical Trial Summary

The use of PRP has dramatically increased in the fields of orthopedics, spine surgery, reconstructive plastic surgery, oral and maxillofacial surgery, and dermatological indications. Nonetheless, its use in the treatment of wounds is not as widespread as in other fields. In this experimental study, the treatment outcome of autologous PRP was assessed in comparison to conventional therapy among patients with chronic venous leg ulcers.

Clinical Trial Description

Venous ulcers are the most common form of leg ulcers which have a significant impact on quality of life and work productivity. In addition, the costs associated with the long-term care of these chronic wounds are substantial. Conventional therapies such as dressings, surgical debridement, compression bandage, and even skin grafting cannot provide satisfactory healing since these treatments are not able to provide necessary growth factors that can modulate healing processes. Autologous platelet-rich plasma (PRP) is a safe, simple, affordable, and less expensive procedure in the treatment of chronic ulcers with reportedly good results. Since it is an autologous method, it is biocompatible and safe. Data from this would help in establishing it as a treatment of choice, thereby leading to a reduction in cost and benefiting the patient both financially and psychologically. PRP is a volume of autologous plasma that has a platelet concentration above baseline i.e., five times more than normal platelet counts. PRP enhances wound healing by promoting the healing process by seven growth factors present in it. They are platelet-derived growth factor (αα, αβ, αβ), fibroblast growth factor, vascular endothelial growth factor, epidermal growth factor, and transforming growth factor. These growth factors are important in modulating mesenchymal cell recruitment, proliferation, and extra-cellular matrix synthesis during the healing process. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05974982
Study type	Interventional
Source	Jinnah Postgraduate Medical Centre
Contact
Status	Completed
Phase	Phase 1
Start date	September 1, 2022
Completion date	May 25, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03903692` - A Comparative Evaluation of a MPS Dressing and a CMC Dressing on Subjects With Lower Extremity Venous Ulcers	N/A
Completed	`NCT03257254` - Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)
Recruiting	`NCT03666754` - Early Glue Saphenous Vein Ablation With Compression Versus Compression Alone in the Healing of the Venous Ulcer	N/A
Withdrawn	`NCT02912858` - Intermittent Pneumatic Compression of the Foot vs Geko Plus R-2 Neuromuscular Electrostimulation Device in Venous Leg Ulcer Patients	N/A
Completed	`NCT02482038` - Geko Venous Leg Ulcer Study	N/A
Completed	`NCT02652572` - Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Venous Leg Ulcers	Phase 1
Unknown status	`NCT01658618` - Safety Study Providing 12 Months Follow-up From First Exposure to HP802-247 in Subjects With Venous Leg Ulcer	N/A
Completed	`NCT05646121` - Suprasorb® A + Ag in the Treatment of Wounds at Risk of Infection and Infected Wounds
Completed	`NCT03077165` - Dose-response Relationship Study of S42909 on Leg Ulcer Healing	Phase 2
Completed	`NCT04461132` - The Effect of Manual Lymphatic Drainage	N/A
Completed	`NCT04011371` - Cyanoacrylate Closure for Treatment of Venous Leg Ulcers	N/A
Not yet recruiting	`NCT03543007` - Evaluating the Safety and Efficacy of GrafixPL™PRIME for the Treatment of Chronic Venous Leg Ulcers	N/A
Completed	`NCT03286140` - Early Venous Reflux Ablation Ulcer Trial	N/A
Recruiting	`NCT05588583` - A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.	N/A
Not yet recruiting	`NCT04613687` - Efficacy and Safety of a New Compression System URGO BD001 in the Treatment of VLU (FREEDOM)	N/A
Recruiting	`NCT05549609` - A Study of XSTEM-VLU in Patients With Difficult-to-heal Venous Leg Ulcers	Phase 1/Phase 2
Recruiting	`NCT05409976` - The GORE® VIAFORT Vascular Stent IVC Study	N/A
Not yet recruiting	`NCT05089890` - Clinical Investigation of Sorbact® Dressings	N/A
Not yet recruiting	`NCT03670329` - Management of Infection Risk in Non-comparative Trial (MINT)	N/A
Completed	`NCT02921750` - Investigation to Evaluate the Efficacy and Safety of Exufiber Versus Aquacel Extra in Moderately or Strongly Exuding Venous and Mixed Ulcers of Predominantly Venous Origin	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Treatment Outcome of Autologous PRP Versus Conventional Therapy Among Patients With Chronic Venous Leg Ulcers

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms